A tale of two yeasts:  Saccharomyces cerevisiae as a therapeutic against candidiasis

Duncan Wilson

doi:10.1080/21505594.2016.1230580

A tale of two yeasts: Saccharomyces cerevisiae as a therapeutic against candidiasis

Duncan Wilson

Research output: Contribution to journal › Editorial

3 Citations (Scopus)

6 Downloads (Pure)

Abstract

Normally a benign commensal colonizer of mucosal surfaces such as the gastrointestinal tract, Candida albicans is also one of the most common fungal pathogens of humans, responsible for both superficial as well as life-threatening invasive infections. Arguably the commonest type of infection caused by C. albicans is vulvovaginal candidiasis (VVC), as it affects 75% of women of childbearing age.1 Sobel JD. Vulvovaginal candidosis. Lancet 2007; 369:1961-71; PMID:17560449; http://dx.doi.org 10.1016/S0140-6736(07)60917-9[CrossRef], [PubMed], [Web of Science ®] And unlike many other manifestations of candidiasis, which are associated with particular immune deficiencies, VVC frequently occurs in otherwise healthy women.

Original language	English
Pages (from-to)	15-17
Number of pages	3
Journal	Virulence
Volume	8
Issue number	1
Early online date	31 Aug 2016
DOIs	https://doi.org/10.1080/21505594.2016.1230580
Publication status	Published - 2017

Keywords

Candida albicans
Saccharomyces cerevisiae
vulvovaginal candidiasis

Access to Document

10.1080/21505594.2016.1230580Licence: CC BY

A tale of two yeasts Saccharomyces cerevisiae as a therapeutic against candidiasis
© 2017 Duncan Wilson. Published with license by Taylor & Francis. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
Final published version, 973 KBLicence: CC BY

Fingerprint Dive into the research topics of 'A tale of two yeasts: <i> Saccharomyces cerevisiae</i> as a therapeutic against candidiasis'. Together they form a unique fingerprint.

Cite this

Wilson, D. (2017). A tale of two yeasts: Saccharomyces cerevisiae as a therapeutic against candidiasis. Virulence, 8(1), 15-17. https://doi.org/10.1080/21505594.2016.1230580

@article{f0b1df7d5b714d098ce61986fa7d8be8,

title = "A tale of two yeasts: Saccharomyces cerevisiae as a therapeutic against candidiasis",

abstract = "Normally a benign commensal colonizer of mucosal surfaces such as the gastrointestinal tract, Candida albicans is also one of the most common fungal pathogens of humans, responsible for both superficial as well as life-threatening invasive infections. Arguably the commonest type of infection caused by C. albicans is vulvovaginal candidiasis (VVC), as it affects 75% of women of childbearing age.1 Sobel JD. Vulvovaginal candidosis. Lancet 2007; 369:1961-71; PMID:17560449; http://dx.doi.org 10.1016/S0140-6736(07)60917-9[CrossRef], [PubMed], [Web of Science {\textregistered}] And unlike many other manifestations of candidiasis, which are associated with particular immune deficiencies, VVC frequently occurs in otherwise healthy women.",

keywords = "Candida albicans, Saccharomyces cerevisiae, vulvovaginal candidiasis",

author = "Duncan Wilson",

note = "Funding DW is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (102549/Z/13/Z), a Wellcome Trust Strategic Award for Medical Mycology and Fungal Immunology (097377/Z/11/Z), the MRC and University of Aberdeen (MR/N006364/1).",

year = "2017",

doi = "10.1080/21505594.2016.1230580",

language = "English",

volume = "8",

pages = "15--17",

journal = "Virulence",

issn = "2150-5594",

publisher = "Landes Bioscience",

number = "1",

}

TY - JOUR

T1 - A tale of two yeasts

T2 - Saccharomyces cerevisiae as a therapeutic against candidiasis

AU - Wilson, Duncan

N1 - Funding DW is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (102549/Z/13/Z), a Wellcome Trust Strategic Award for Medical Mycology and Fungal Immunology (097377/Z/11/Z), the MRC and University of Aberdeen (MR/N006364/1).

PY - 2017

Y1 - 2017

N2 - Normally a benign commensal colonizer of mucosal surfaces such as the gastrointestinal tract, Candida albicans is also one of the most common fungal pathogens of humans, responsible for both superficial as well as life-threatening invasive infections. Arguably the commonest type of infection caused by C. albicans is vulvovaginal candidiasis (VVC), as it affects 75% of women of childbearing age.1 Sobel JD. Vulvovaginal candidosis. Lancet 2007; 369:1961-71; PMID:17560449; http://dx.doi.org 10.1016/S0140-6736(07)60917-9[CrossRef], [PubMed], [Web of Science ®] And unlike many other manifestations of candidiasis, which are associated with particular immune deficiencies, VVC frequently occurs in otherwise healthy women.

AB - Normally a benign commensal colonizer of mucosal surfaces such as the gastrointestinal tract, Candida albicans is also one of the most common fungal pathogens of humans, responsible for both superficial as well as life-threatening invasive infections. Arguably the commonest type of infection caused by C. albicans is vulvovaginal candidiasis (VVC), as it affects 75% of women of childbearing age.1 Sobel JD. Vulvovaginal candidosis. Lancet 2007; 369:1961-71; PMID:17560449; http://dx.doi.org 10.1016/S0140-6736(07)60917-9[CrossRef], [PubMed], [Web of Science ®] And unlike many other manifestations of candidiasis, which are associated with particular immune deficiencies, VVC frequently occurs in otherwise healthy women.

KW - Candida albicans

KW - Saccharomyces cerevisiae

KW - vulvovaginal candidiasis

U2 - 10.1080/21505594.2016.1230580

DO - 10.1080/21505594.2016.1230580

M3 - Editorial

VL - 8

SP - 15

EP - 17

JO - Virulence

JF - Virulence

SN - 2150-5594

IS - 1

ER -